PACB - Pacific Biosciences of California, Inc. - Alternativkedja

Pacific Biosciences of California, Inc.
US ˙ NasdaqGS ˙ US69404D1081

Utgång
Calls för September 12, 2025
Kontrakt Strike Bud Fråga Senaste Volym OI IV Delta Gamma Theta Theta Rho
PACB20250919C00000500 0.50 0.55 0.75 0.00 0 26 276.35% 1.00 0.05 -0.00 0.00 0.00
PACB20250919C00001000 1.00 0.00 0.25 0.20 1 2,268 245.67% 0.74 0.82 -0.01 0.00 0.00
PACB20250919C00001500 1.50 0.00 0.05 0.03 25 10,558 172.03% 0.19 0.96 -0.01 0.00 0.00
PACB20250919C00002000 2.00 0.00 0.05 0.00 0 2,300 286.30% 0.13 0.45 -0.01 0.00 0.00
PACB20250919C00003000 3.00 0.00 0.05 0.02 20 810 423.83% 0.10 0.25 -0.01 0.00 0.00
PACB20250919C00004000 4.00 0.00 0.10 0.00 0 149 592.69% 0.14 0.23 -0.01 0.00 0.00
PACB20250919C00005000 5.00 0.00 0.10 0.00 0 135 661.39% 0.14 0.20 -0.02 0.00 0.00
Puts för September 12, 2025
Kontrakt Strike Bud Fråga Senaste Volym OI IV Delta Gamma Theta Theta Rho
PACB20250919P00000500 0.50 0.00 0.45 0.00 0 100 0.00% 0.00 0.00 0.00 0.00 0.00
PACB20250919P00001000 1.00 0.00 0.05 0.03 61 3,863 142.00% -0.18 1.16 -0.00 0.00 0.00
PACB20250919P00001500 1.50 0.25 0.40 0.00 0 4,511 265.34% -0.69 0.84 -0.01 0.00 -0.00
PACB20250919P00002000 2.00 0.00 0.90 0.84 60 1,093 276.76% -0.89 0.45 -0.01 0.00 -0.00
PACB20250919P00003000 3.00 1.70 1.90 0.00 0 2,614 553.99% -0.80 0.32 -0.02 0.00 -0.00
PACB20250919P00004000 4.00 2.70 2.95 0.00 0 1,796 757.60% -0.74 0.27 -0.03 0.00 -0.00
PACB20250919P00005000 5.00 3.70 4.00 0.00 0 50 0.00% 0.00 0.00 0.00 0.00 0.00
Other Listings
MX:PACB
DE:P09
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista